Evidence map›Paper›PMID 36133348›Full record

ArticleNanoscale advances2022

The protein corona reduces the anticancer effect of graphene oxide in HER-2-positive cancer cells.

Lishan Cui, Erica Quagliarini, Siyao Xiao, Francesca Giulimondi, Serena Renzi, Luca Digiacomo, Giulio Caracciolo, Junbiao Wang, Augusto Amici, Cristina Marchini and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nanoscale advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Lishan CuiSchool of Biosciences and Veterinary Medicine, University of Camerino 62032 Camerino Italy cristina.marchini@unicam.it.ORCID https://orcid.org/0000-0001-7647-1376
Erica QuagliariniNanoDelivery Lab, Department of Molecular Medicine, Sapienza University of Rome Viale Regina Elena 291 00161 Rome Italy daniela.pozzi@uniroma1.it.
Siyao XiaoNanoDelivery Lab, Department of Molecular Medicine, Sapienza University of Rome Viale Regina Elena 291 00161 Rome Italy daniela.pozzi@uniroma1.it.ORCID https://orcid.org/0000-0001-6418-9568
Francesca GiulimondiNanoDelivery Lab, Department of Molecular Medicine, Sapienza University of Rome Viale Regina Elena 291 00161 Rome Italy daniela.pozzi@uniroma1.it.
Serena RenziNanoDelivery Lab, Department of Molecular Medicine, Sapienza University of Rome Viale Regina Elena 291 00161 Rome Italy daniela.pozzi@uniroma1.it.
Luca DigiacomoNanoDelivery Lab, Department of Molecular Medicine, Sapienza University of Rome Viale Regina Elena 291 00161 Rome Italy daniela.pozzi@uniroma1.it.
Giulio CaraccioloNanoDelivery Lab, Department of Molecular Medicine, Sapienza University of Rome Viale Regina Elena 291 00161 Rome Italy daniela.pozzi@uniroma1.it.ORCID https://orcid.org/0000-0002-8636-4475
Junbiao WangSchool of Biosciences and Veterinary Medicine, University of Camerino 62032 Camerino Italy cristina.marchini@unicam.it.
Augusto AmiciSchool of Biosciences and Veterinary Medicine, University of Camerino 62032 Camerino Italy cristina.marchini@unicam.it.
Cristina MarchiniSchool of Biosciences and Veterinary Medicine, University of Camerino 62032 Camerino Italy cristina.marchini@unicam.it.
Daniela PozziNanoDelivery Lab, Department of Molecular Medicine, Sapienza University of Rome Viale Regina Elena 291 00161 Rome Italy daniela.pozzi@uniroma1.it.ORCID https://orcid.org/0000-0001-6158-5880
Sapienza University of Rome · ITUniversità di Camerino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the last decade, graphene oxide (GO)-based nanomaterials have attracted much attention for their potential anti-cancer properties against various cancer cell types. However, while

Identifiers

PMID36133348
PMCPMC9470059
OpenAlexW4293171103

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.